Stock Update (NASDAQ:CLVS): Clovis Oncology Inc Announces Proposed Offering of Common Stock

Clovis Oncology Inc (NASDAQ:CLVS) announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology.

Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including sales and marketing expenses associated with Rubraca® (rucaparib) in the United States and, if approved by the European Medicines Agency (EMA), in Europe, funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.

J. P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint book-running managers for the offering. Stifel and SunTrust Robinson Humphrey are acting as co-managers for the offering.

In addition, Clovis Oncology intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Shares of Clovis Oncology closed today at $87.88, up $27.91 or 46.54%. CLVS has a 1-year high of $91 and a 1-year low of $11.57. The stock’s 50-day moving average is $54.36 and its 200-day moving average is $55.44.

Overall, one research analyst has assigned a Hold rating and 7 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $76.5 which is -12.9% under where the stock opened today.

Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: Rociletinib, Rucaparib and Lucitani.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts